$ cat ./records/funded-the-path-malaria-vaccine-initiative-with-107-6-million-to--2004.txt
Funded the PATH Malaria Vaccine Initiative with $107.6 million to advance GlaxoSmithKline's RTS,S vaccine
[RECORD.TXT] · cat --full
The Gates Foundation provided $107.6 million to the PATH Malaria Vaccine Initiative to advance GlaxoSmithKline's RTS,S malaria vaccine candidate through clinical trials in Africa. The investment was essential to sustaining a program that lacked sufficient commercial return to attract pharmaceutical funding at scale. This long-term commitment culminated in the WHO's 2021 recommendation of Mosquirix — the world's first vaccine against any parasitic disease — following Phase 3 trials in over 15,000 children across seven African countries.
Source: https://www.gatesfoundation.org/our-work/programs/global-health/malaria
Free forever · No ads · Solo developer
If this was worth a read, help make the next entry possible.
Every entry in this archive was researched, verified, and written by one person — for free. No corporate funding. No ad revenue. Just a developer who believes verified history should be accessible to everyone. Your donation directly funds new entries.
Crypto accepted · No subscription required
← Previous
Awarded $82.9 million to the International AIDS Vaccine Initiative to accelerate HIV vaccine research
Next →
Pledged additional $50 million to the Global Fund at the G8 summit — bringing total to $150 million
[CROSS_REFERENCES] · grep --category='Global Health'
Related Accomplishments
January 2026
Gates-backed World Mosquito Program reaches 16 million people protected from dengue via Wolbachia method
The World Mosquito Program — backed in part by the Gates Foundation — announced in January 2026 that its Wolbachia-infected mosquito releases had reached over 16.1 million people across multiple countries, including Colombia, Indonesia, Brazil, Sri Lanka, Fiji, Vanuatu, and Vietnam. Wolbachia-carrying Aedes aegypti mosquitoes — which block dengue, Zika, chikungunya, and yellow fever transmission — had established self-sustaining populations in treated cities without requiring ongoing releases. Gold-standard randomised trials in Indonesia showed a 77% reduction in dengue incidence. The program represented one of the largest and most cost-effective vector control deployments in history.
2025
Gates-Funded Monoclonal Antibody Shows Early Promise as a Single-Shot Malaria Shield
[ARCHIVE_FUNDING] · INDEPENDENT · NO ADS
One developer. >300 verified entries. Zero ads. Forever free.
No sponsors, no paywall, no algorithm. If this archive has been useful to you, reader support is what keeps it running.